Value of preoperative 18F-FDG PET metabolic heterogeneity parameters in predicting tumor deposits in colorectal cancer
10.3760/cma.j.cn431274-20240819-01278
- VernacularTitle:术前 18F-FDG PET代谢异质性参数预测结直肠癌肿瘤沉积的价值
- Author:
Qiaoliang CHEN
1
;
Jing CHEN
;
Di LIANG
;
Ruihe LAI
;
Jian HE
;
Shuangxiu TAN
Author Information
1. 南京鼓楼医院(南京大学医学院附属鼓楼医院)核医学科，南京 210008
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Tumor deposit;
Tumor heterogeneity;
Positron emission tomography
- From:
Journal of Chinese Physician
2025;27(9):1376-1381
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the value of preoperative 18F-fluorodeoxyglucose ( 18F-FDG) positron emission tomography (PET) metabolic heterogeneity parameters in predicting tumor deposits (TD) in colorectal cancer (CRC). Methods:A retrospective analysis was conducted on 91 CRC patients who underwent surgical treatment at the Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School from February 2013 to March 2024. All patients underwent preoperative 18F-FDG PET/CT examination. The LIFEx-7.5.15 software was used to delineate the primary lesion with 40% of maximum standardized uptake value (SUV max) as the relative threshold, and metabolic parameters were extracted. Intratumoral metabolic heterogeneity parameters included cumulative SUV histogram area under the curve (AUC-CSH), heterogeneity index (HI), heterogeneity factor (HF), and coefficient of variation (CV). The presence of TD was confirmed by postoperative pathological examination. Differences in data between the TD group and non-TD (NTD) group were compared. Binary logistic regression analysis was used to identify independent risk factors for TD, and receiver operating characteristic (ROC) curve was used to evaluate the predictive efficacy of each parameter for TD. Results:Postoperative pathological diagnosis showed that 27 patients were included in the TD group and 64 in the NTD group. There were statistically significant differences between the TD group and NTD group in CV ( Z=-3.145, P=0.002) and the proportion of patients with carcinoembryonic antigen (CEA) >10 ng/ml (χ 2=10.751, P=0.001), while no statistically significant differences were found in HI, HF, or AUC-CSH (all P>0.05). Binary logistic regression analysis showed that CV was an independent risk factor for TD. ROC curve analysis showed that the area under the ROC curve (AUC) of CV for predicting TD was 0.709(95% CI: 0.593-0.826), which was higher than that of other metabolic heterogeneity parameters. Conclusions:The preoperative 18F-FDG PET/CT metabolic heterogeneity parameter CV has value in predicting TD in CRC patients.
